论文部分内容阅读
本文依据５９例肺癌骨转移患者的临床资料，总结分析了肺癌骨转移的特点，着重探讨了骨膦与化疗和放疗联合治疗肺癌骨转移的疗效。结果示：骨膦治疗组３９例止痛总有效率为８７．２％，非骨膦治疗组２０例止痛总有效率为６０％，两者有显著差异（Ｐ〈０．０５）；骨膦治疗组的平均生存期（８．５个月）较非骨膦治疗组（５个月）明显延长（Ｐ〈０．０５）；骨膦治疗组较非骨膦治疗组无明显的毒性反应。另外骨膦用药的时间和疗程对疗效都有一定影响。
Based on the clinical data of 59 patients with bone metastases from lung cancer, this article summarizes the characteristics of bone metastases from lung cancer, and focuses on the efficacy of bone phosphine combined with chemotherapy and radiotherapy in the treatment of bone metastases from lung cancer. The results showed that the total effective rate of analgesia was 87.2% in the bone phosphine treatment group and 60% in the non-bone phosphine treatment group. There was a significant difference between the two groups (P<0.05); The average survival time of the group (8.5 months) was significantly longer than that of the non-bone phosphine treatment group (5 months) (P<0.05). There was no obvious toxic reaction in the bone phosphine treatment group compared with the non-bone phosphine treatment group. In addition, the time and course of treatment with bone phosphine have certain effects on the curative effect.